PAX6-T373, Polyclonal Antibody

Paired box protein Pax-6; Aniridia type II protein; Oculorhombin; PAX6; AN2

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit Ig

Rabbit

This PAX6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 352-380 amino acids from human PAX6.

Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Vial Concentration: 0.25 (lot specific)

Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.

Small volumes of anti-PAX6 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

PAX6 encodes paired box gene 6, one of many human homologs of the Drosophila melanogaster gene prd. In addition to the hallmark feature of this gene family, a conserved paired box domain, the encoded protein also contains a homeo box domain. Both domains are known to bind DNA, and function as regulators of gene transcription. This gene is expressed in the developing nervous system, and in developing eyes. Mutations in this gene are known to cause ocular disorders such as aniridia and Peter's anomaly.

Developmental Biology; Neuroscience; Signal Transduction

Western Blot (WB), ELISA (EIA), Immunohistochemistry (IHC), Immunofluorescence (IF)

WB~~1:1000

Western blot analysis of PAX6-T373 in Y79 cell line lysates (35ug/lane). PAX6 (arrow) was detected using the purified Pab.

Western blot analysis of PAX6 (arrow) using rabbit polyclonal PAX6 Antibody (T373). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the PAX6 gene.

PAX6-T373 Antibody immunohistochemistry analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the PAX6-T373 Antibody for immunohistochemistry. Clinical relevance has not been evaluated.

Confocal immunofluorescent analysis of PAX6-T373 Antibody with Hela cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).DAPI was used to stain the cell nuclear (blue).

46683

paired box 6

paired box protein Pax-6

Paired box protein Pax-6

AN2  [Similar Products]

PAX6_HUMAN

This gene encodes paired box gene 6, one of many human homologs of the Drosophila melanogaster gene prd. In addition to the hallmark feature of this gene family, a conserved paired box domain, the encoded protein also contains a homeo box domain. Both domains are known to bind DNA and function as regulators of gene transcription. This gene is expressed in the developing nervous system, and in developing eyes. Mutations in this gene are known to cause ocular disorders such as aniridia and Peter's anomaly. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, May 2012]

PAX6: Transcription factor with important functions in the development of the eye, nose, central nervous system and pancreas. Required for the differentiation of pancreatic islet alpha cells. Competes with PAX4 in binding to a common element in the glucagon, insulin and somatostatin promoters. Regulates specification of the ventral neuron subtypes by establishing the correct progenitor domains. Isoform 5a appears to function as a molecular switch that specifies target genes. Defects in PAX6 are the cause of aniridia (AN). A congenital, bilateral, panocular disorder characterized by complete absence of the iris or extreme iris hypoplasia. Aniridia is not just an isolated defect in iris development but it is associated with macular and optic nerve hypoplasia, cataract, corneal changes, nystagmus. Visual acuity is generally low but is unrelated to the degree of iris hypoplasia. Glaucoma is a secondary problem causing additional visual loss over time. Defects in PAX6 are a cause of Peters anomaly (PAN). Peters anomaly consists of a central corneal leukoma, absence of the posterior corneal stroma and Descemet membrane, and a variable degree of iris and lenticular attachments to the central aspect of the posterior cornea. Defects in PAX6 are a cause of foveal hypoplasia (FOVHYP). Foveal hypoplasia can be isolated or associated with presenile cataract. Inheritance is autosomal dominant. Defects in PAX6 are a cause of keratitis hereditary (KERH). An ocular disorder characterized by corneal opacification, recurrent stromal keratitis and vascularization. Defects in PAX6 are a cause of coloboma of iris choroid and retina (COI); also known as uveoretinal coloboma. Ocular colobomas are a set of malformations resulting from abnormal morphogenesis of the optic cup and stalk, and the fusion of the fetal fissure (optic fissure). Severe colobomatous malformations may cause as much as 10% of the childhood blindness. The clinical presentation of ocular coloboma is variable. Some individuals may present with minimal defects in the anterior iris leaf without other ocular defects. More complex malformations create a combination of iris, uveoretinal and/or optic nerve defects without or with microphthalmia or even anophthalmia. Defects in PAX6 are a cause of coloboma of optic nerve (COLON). Defects in PAX6 are a cause of bilateral optic nerve hypoplasia (BONH); also known as bilateral optic nerve aplasia. A congenital anomaly in which the optic disc appears abnormally small. It may be an isolated finding or part of a spectrum of anatomic and functional abnormalities that includes partial or complete agenesis of the septum pellucidum, other midline brain defects, cerebral anomalies, pituitary dysfunction, and structural abnormalities of the pituitary. Defects in PAX6 are a cause of aniridia cerebellar ataxia and mental deficiency (ACAMD); also known as Gillespie syndrome. A rare condition consisting of partial rudimentary iris, cerebellar impairment of the ability to perform coordinated voluntary movements, and mental retardation. Belongs to the paired homeobox family. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Motility/polarity/chemotaxis; Transcription factor; DNA-binding

Chromosomal Location of Human Ortholog: 11p13

Cellular Component: nucleoplasm; cytoplasm; nuclear chromatin; nucleus

Molecular Function: histone acetyltransferase binding; protein binding; DNA binding; AT DNA binding; ubiquitin protein ligase binding; double-stranded DNA binding; ubiquitin-protein ligase activity; chromatin binding; transcription factor activity; protein kinase binding; transcription factor binding

Biological Process: central nervous system development; positive regulation of transcription, DNA-dependent; protein ubiquitination; cell fate determination; glucose homeostasis; positive regulation of epithelial cell differentiation; cerebellum development; neural crest cell migration; positive regulation of neuroblast proliferation; positive regulation of cell fate specification; neuron fate commitment; oligodendrocyte cell fate specification; interkinetic nuclear migration; keratinocyte differentiation; forebrain-midbrain boundary formation; organ morphogenesis; negative regulation of neuron differentiation; eye photoreceptor cell development; response to ethanol; cellular response to insulin stimulus; retina development in camera-type eye; rhombomere morphogenesis; forebrain anterior/posterior pattern formation; regulation of transcription from RNA polymerase II promoter involved in somatic motor neuron fate commitment; positive regulation of transcription from RNA polymerase II promoter; lens development in camera-type eye; transcription from RNA polymerase II promoter; axon guidance; regulation of asymmetric cell division; neuron migration; dorsal/ventral axis specification; forebrain dorsal/ventral pattern formation; cerebral cortex regionalization; negative regulation of transcription from RNA polymerase II promoter; negative regulation of neurogenesis; astrocyte differentiation; visual perception; establishment of mitotic spindle orientation; negative regulation of protein amino acid phosphorylation; salivary gland morphogenesis; response to wounding; lacrimal gland development; regulation of timing of cell differentiation; negative regulation of epithelial cell proliferation; blood vessel development; smoothened signaling pathway; olfactory bulb development; eye development; pituitary gland development; commitment of a neuronal cell to a specific type of neuron in the forebrain; protein localization in organelle; regulation of transcription from RNA polymerase II promoter involved in ventral spinal cord interneuron specification; regulation of transcription from RNA polymerase II promoter involved in spinal cord motor neuron fate specification; embryonic camera-type eye morphogenesis

Disease: Wilms Tumor, Aniridia, Genitourinary Anomalies, And Mental Retardation Syndrome; Peters Anomaly; Coloboma Of Optic Nerve; Keratitis, Hereditary; Aniridia, Cerebellar Ataxia, And Mental Retardation; Foveal Hypoplasia 1; Aniridia; Optic Nerve Hypoplasia, Bilateral

Zhang, Y., et al. J. Biol. Chem. 285(4):2527-2536(2010)
McGeachie, M., et al. Circulation 120(24):2448-2454(2009)
Schmidt-Sidor, B., et al. Folia Neuropathol 47(4):372-382(2009)
Ng, T.K., et al. Mol. Vis. 15, 2239-2248 (2009)

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.